In this review, we will provide a comprehensive update on CD47-targeting antibodies for hematological malignancies, including monoclonal and bi-specific antibodies, with a special emphasis on agents in clinical investigation (Fig. 1). This evidence concerns the gene CD47 and hematologic disorder.